Physician profile
Mary E Rahn
NPI 1164502191
$1,257.98
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $57.32 · 2021: $369 · 2022: $718.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $339.31 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $160.48 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $137.22 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $101.43 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $92.60 | 2020-2022 | |
| Alkermes, INC. | $86.67 | 2022 | |
| Sunovion Pharmaceuticals INC. | $77.11 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.79 | 2019-2022 | |
| Almatica Pharma LLC | $53.04 | 2022 | |
| Lundbeck LLC | $40.75 | 2022 | |
| Indivior INC. | $33.88 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $21.86 | 2022 | |
| Ironshore Pharmaceuticals INC. | $20.03 | 2022 | |
| Noven Therapeutics, LLC | $12.49 | 2021 | |
| Eisai INC. | $11.32 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Rahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.